{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:28:50Z","timestamp":1793305730297,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jacc.2022.02.035","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T14:27:38Z","timestamp":1650896858000},"page":"1660-1671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior\u00a0Myocardial Infarction"],"prefix":"10.1016","volume":"79","author":[{"given":"Prakriti","family":"Gaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph. Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Ketchum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Juliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ralph T.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Granowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice M.A.C.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2022.02.035_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2022.02.035_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.02.035_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management","volume":"72","author":"Ganda","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib4","doi-asserted-by":"crossref","first-page":"100997","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jacc.2022.02.035_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.02.035_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3032","article-title":"Adherence to guideline medication recommendations to prevent atherosclerotic cardiovascular disease progression among adults with prior myocardial infarction","volume":"3","author":"Arnold","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2022.02.035_bib7","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia","volume":"78","author":"Virani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib8","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","article-title":"Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association","volume":"141","author":"Arnold","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.02.035_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.02.035_bib10","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.02.035_bib11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","article-title":"Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries","volume":"2","author":"Colantonio","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib12","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/clc.23437","article-title":"Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?","volume":"43","author":"Ferri\u00e8res","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib13","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/ehjcvp\/pvaa118","article-title":"REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results","volume":"7","author":"Olshansky","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2022.02.035_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.02.035_bib15","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.02.035_bib16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/cvr\/cvaa184","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results","volume":"117","author":"Budoff","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2022.02.035_bib17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2022.02.035_bib18","doi-asserted-by":"crossref","first-page":"100106","DOI":"10.1016\/j.jlr.2021.100106","article-title":"EPA and DHA containing phospholipids have contrasting effects on membrane structure","volume":"62","author":"Sherratt","year":"2021","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2022.02.035_bib19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.2021.0824","article-title":"Omega-3 fatty acids effect on major cardiovascular events in patients at high cardiovascular risk","volume":"325","author":"Olshansky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2022.02.035_bib20","doi-asserted-by":"crossref","first-page":"102337","DOI":"10.1016\/j.plefa.2021.102337","article-title":"Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability","volume":"173","author":"Sherratt","year":"2021","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.jacc.2022.02.035_bib21","doi-asserted-by":"crossref","first-page":"103040","DOI":"10.1016\/j.isci.2021.103040","article-title":"A\u00a0randomized trial of icosapent ethyl in ambulatory patients with COVID-19","author":"Kosmopoulos","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jacc.2022.02.035_bib22","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/eurheartj\/ehz778","article-title":"Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics","volume":"41","author":"Boden","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.02.035_bib23","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jacc.2021.08.009","article-title":"Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT","volume":"78","author":"Gaba","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib24","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2019.08.007","article-title":"Reply: ischemic event reduction and triglycerides","volume":"74","author":"Bhatt","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib25","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.02.035_bib26","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.02.035_bib27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/eurheartj\/ehz179","article-title":"REDUCE-IT: residual cardiovascular risk in statin-treated patients with elevated triglycerides: now we can REDUCE-IT!","volume":"40","author":"Bhatt","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.02.035_bib28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib29","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Reduction in revascularization with icosapent ethyl","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.02.035_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pcad.2021.08.003","article-title":"The role of eicosapentaenoic acid in reducing important cardiovascular events, including coronary revascularization","volume":"69","author":"Bhatt","year":"2021","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2022.02.035_bib33","doi-asserted-by":"crossref","first-page":"J1","DOI":"10.1093\/eurheartj\/suaa114","article-title":"Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside","volume":"22","author":"Bhatt","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jacc.2022.02.035_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14740338.2021.1954158","article-title":"Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides","volume":"21","author":"Pareek","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jacc.2022.02.035_bib35","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH Randomized Clinical Trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2022.02.035_bib36","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2021.1489","article-title":"Effect of marine omega-3 fatty acid and vitamin D supplementation on incident atrial fibrillation: a randomized clinical trial","volume":"325","author":"Albert","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2022.02.035_bib37","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.bbamem.2016.10.002","article-title":"Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes","volume":"1858","author":"Mason","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacc.2022.02.035_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","article-title":"Effect of alirocumab on mortality after acute coronary syndromes","volume":"140","author":"Steg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.02.035_bib39","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.02.035_bib40","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.02.035_bib41","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.02.035_bib42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.02.035_bib43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jacc.2021.04.083","article-title":"Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease","volume":"78","author":"Eikelboom","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib44","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.02.035_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11892-020-01343-7","article-title":"The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction","volume":"20","author":"Wang","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jacc.2022.02.035_bib46","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.jacc.2020.09.005","article-title":"A\u00a0Revolution in omega-3 fatty acid research","volume":"76","author":"Bhatt","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722005538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722005538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:49:11Z","timestamp":1760017751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109722005538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":46,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0735109722005538"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2022.02.035","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior\u00a0Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2022.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}